GLTO Galecto | $12.71
-1.7% | 8/15/2023 | Downgraded by | SVB Securities | - | Outperform -> Market Perform | | Low | View details for SVB Securities rating of Galecto (NASDAQ:GLTO) on 8/15/2023 |
CNTA Centessa Pharmaceuticals | $16.39
-3.5% | 8/15/2023 | Target Raised by | SVB Securities | - | Outperform -> Outperform | $6.00 -> $11.00 | Low | View details for SVB Securities rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 8/15/2023 |
TSBX Turnstone Biologics | $0.66
-0.2% | 8/15/2023 | Initiated by | SVB Securities | - | Market Perform | | Low | View details for SVB Securities rating of Turnstone Biologics (NASDAQ:TSBX) on 8/15/2023 |
CYTK Cytokinetics | $56.56
+1.2% | 8/15/2023 | Initiated by | SVB Securities | - | Outperform | $58.00 | Low | View details for SVB Securities rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
DSGN Design Therapeutics | $5.60
+1.1% | 8/15/2023 | Downgraded by | SVB Securities | - | Outperform -> Market Perform | $6.00 | Low | View details for SVB Securities rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
RLAY Relay Therapeutics | $8.16
+7.4% | 8/8/2023 | Initiated by | SVB Securities | - | Outperform | | Low | View details for SVB Securities rating of Relay Therapeutics (NASDAQ:RLAY) on 8/8/2023 |
|
NUVL Nuvalent | $110.83
+26.7% | 8/8/2023 | Initiated by | SVB Securities | - | Market Perform | $42.00 | Low | View details for SVB Securities rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $37.24
-0.6% | 8/8/2023 | Initiated by | SVB Securities | - | Outperform | $33.00 | Low | View details for SVB Securities rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
EXEL Exelixis | $27.44
+3.7% | 8/8/2023 | Initiated by | SVB Securities | - | Market Perform | $18.00 | Low | View details for SVB Securities rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
QTRX Quanterix | $12.79
-0.2% | 8/8/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $30.00 | Low | View details for SVB Securities rating of Quanterix (NASDAQ:QTRX) on 8/8/2023 |
NVCR NovoCure | $17.76
-4.4% | 8/4/2023 | Initiated by | SVB Securities | - | Outperform | $51.00 | Low | View details for SVB Securities rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
BLTE Belite Bio | $48.62
-0.4% | 7/26/2023 | Initiated by | SVB Securities | - | Outperform | $25.00 | Low | View details for SVB Securities rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
NBIX Neurocrine Biosciences | $122.65
+0.3% | 7/24/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $115.00 -> $125.00 | Low | View details for SVB Securities rating of Neurocrine Biosciences (NASDAQ:NBIX) on 7/24/2023 |
CYRX Cryoport | $8.36
+0.1% | 7/13/2023 | Downgraded by | SVB Securities | - | Outperform -> Market Perform | $30.00 -> $10.00 | Low | View details for SVB Securities rating of Cryoport (NASDAQ:CYRX) on 7/13/2023 |
BMY Bristol-Myers Squibb | $50.02
+1.8% | 7/10/2023 | Initiated by | SVB Securities | - | Market Perform | $66.00 | Low | View details for SVB Securities rating of Bristol-Myers Squibb (NYSE:BMY) on 7/10/2023 |
MLTX MoonLake Immunotherapeutics | $50.76
-0.7% | 6/26/2023 | Target Raised by | SVB Securities | - | | $28.00 -> $56.00 | Low | View details for SVB Securities rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 6/26/2023 |
EHAB Enhabit | $8.00
-1.2% | 6/20/2023 | Initiated by | SVB Securities | - | Underperform | $10.00 | Low | View details for SVB Securities rating of Enhabit (NYSE:EHAB) on 6/20/2023 |
PEPG PepGen | $9.14
-3.6% | 6/14/2023 | Target Lowered by | SVB Securities | - | | $33.00 -> $28.00 | Low | View details for SVB Securities rating of PepGen (NASDAQ:PEPG) on 6/14/2023 |
UNH UnitedHealth Group | $588.91
-0.9% | 6/14/2023 | Target Lowered by | SVB Securities | - | | $625.00 -> $560.00 | Low | View details for SVB Securities rating of UnitedHealth Group (NYSE:UNH) on 6/14/2023 |
OCS Oculis | $11.93
-0.1% | 6/12/2023 | Initiated by | SVB Securities | - | Outperform | | Low | View details for SVB Securities rating of Oculis (NASDAQ:OCS) on 6/12/2023 |
CVAC CureVac | $3.22
-6.4% | 6/8/2023 | Initiated by | SVB Securities | - | Outperform | $13.00 | Low | View details for SVB Securities rating of CureVac (NASDAQ:CVAC) on 6/8/2023 |
CSTL Castle Biosciences | $31.18
| 6/5/2023 | Target Lowered by | SVB Securities | - | | $50.00 -> $35.00 | Low | View details for SVB Securities rating of Castle Biosciences (NASDAQ:CSTL) on 6/5/2023 |
BPMC Blueprint Medicines | $86.07
-3.2% | 6/5/2023 | Downgraded by | SVB Securities | - | Market Perform -> Underperform | $48.00 -> $43.00 | Low | View details for SVB Securities rating of Blueprint Medicines (NASDAQ:BPMC) on 6/5/2023 |
ELEV Elevation Oncology | $0.62
+2.2% | 5/30/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $5.00 -> $8.00 | Low | View details for SVB Securities rating of Elevation Oncology (NASDAQ:ELEV) on 5/30/2023 |
UHS Universal Health Services | $235.20
+1.1% | 5/26/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $147.00 -> $170.00 | Low | View details for SVB Securities rating of Universal Health Services (NYSE:UHS) on 5/26/2023 |
A Agilent Technologies | $138.70
+1.0% | 5/24/2023 | Target Lowered by | SVB Securities | - | Outperform | $170.00 -> $145.00 | Low | View details for SVB Securities rating of Agilent Technologies (NYSE:A) on 5/24/2023 |
VECT VectivBio | $16.85
| 5/23/2023 | Downgraded by | SVB Securities | - | Outperform -> Market Perform | | Low | View details for SVB Securities rating of VectivBio (NASDAQ:VECT) on 5/23/2023 |
ARWR Arrowhead Pharmaceuticals | $20.61
-4.1% | 5/12/2023 | Downgraded by | SVB Securities | - | Outperform -> Market Perform | $40.00 | Low | View details for SVB Securities rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/12/2023 |
VIR Vir Biotechnology | $7.95
-2.0% | 5/5/2023 | Target Lowered by | SVB Securities | - | | $43.00 -> $42.00 | Low | View details for SVB Securities rating of Vir Biotechnology (NASDAQ:VIR) on 5/5/2023 |
REGN Regeneron Pharmaceuticals | $1,154.88
+0.1% | 5/5/2023 | Target Lowered by | SVB Securities | - | | $976.00 -> $895.00 | Low | View details for SVB Securities rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 5/5/2023 |
PRVA Privia Health Group | $18.77
-0.9% | 5/5/2023 | Target Raised by | SVB Securities | - | | $39.00 -> $40.00 | Low | View details for SVB Securities rating of Privia Health Group (NASDAQ:PRVA) on 5/5/2023 |
LNTH Lantheus | $106.32
+0.7% | 5/5/2023 | Target Raised by | SVB Securities | - | | $120.00 -> $127.00 | Low | View details for SVB Securities rating of Lantheus (NASDAQ:LNTH) on 5/5/2023 |
AMED Amedisys | $96.92
+0.0% | 5/5/2023 | Target Lowered by | SVB Securities | - | | $96.00 -> $81.00 | Low | View details for SVB Securities rating of Amedisys (NASDAQ:AMED) on 5/5/2023 |
ALHC Alignment Healthcare | $11.63
-2.2% | 5/5/2023 | Target Lowered by | SVB Securities | - | | $24.00 -> $12.00 | Low | View details for SVB Securities rating of Alignment Healthcare (NASDAQ:ALHC) on 5/5/2023 |
AGIO Agios Pharmaceuticals | $45.69
-2.1% | 5/5/2023 | Target Lowered by | SVB Securities | - | | $37.00 -> $34.00 | Low | View details for SVB Securities rating of Agios Pharmaceuticals (NASDAQ:AGIO) on 5/5/2023 |
ABCL AbCellera Biologics | $2.70
-1.8% | 5/5/2023 | Target Lowered by | SVB Securities | - | | $16.00 -> $15.00 | Low | View details for SVB Securities rating of AbCellera Biologics (NASDAQ:ABCL) on 5/5/2023 |
LLY Eli Lilly and Company | $920.72
-0.3% | 5/1/2023 | Target Raised by | SVB Securities | - | | $410.00 -> $458.00 | Low | View details for SVB Securities rating of Eli Lilly and Company (NYSE:LLY) on 5/1/2023 |
DHR Danaher | $276.18
+0.7% | 5/1/2023 | Initiated by | SVB Securities | - | Outperform | $300.00 | Low | View details for SVB Securities rating of Danaher (NYSE:DHR) on 5/1/2023 |
HUM Humana | $313.70
-2.4% | 4/27/2023 | Target Lowered by | SVB Securities | - | | $640.00 -> $600.00 | Low | View details for SVB Securities rating of Humana (NYSE:HUM) on 4/27/2023 |
ALVR AlloVir | $0.76
+1.0% | 4/26/2023 | Target Raised by | SVB Securities | - | | $16.00 -> $19.00 | Low | View details for SVB Securities rating of AlloVir (NASDAQ:ALVR) on 4/26/2023 |
My big AI project… (Ad) On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron.
This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016. Just click here to register. |
PRTA Prothena | $22.04
-0.3% | 4/24/2023 | Initiated by | SVB Securities | - | Outperform | $80.00 | Low | View details for SVB Securities rating of Prothena (NASDAQ:PRTA) on 4/24/2023 |
MRUS Merus | $50.07
-0.1% | 4/17/2023 | Target Raised by | SVB Securities | - | Outperform | $35.00 -> $48.00 | Low | View details for SVB Securities rating of Merus (NASDAQ:MRUS) on 4/17/2023 |
FDMT 4D Molecular Therapeutics | $16.45
+1.2% | 4/13/2023 | Target Lowered by | SVB Securities | - | Market Perform | $14.00 -> $13.00 | Low | View details for SVB Securities rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 4/13/2023 |
BBIO BridgeBio Pharma | $26.33
+0.6% | 4/13/2023 | Target Raised by | SVB Securities | - | Outperform | $25.00 -> $27.00 | Low | View details for SVB Securities rating of BridgeBio Pharma (NASDAQ:BBIO) on 4/13/2023 |
ARWR Arrowhead Pharmaceuticals | $20.61
-4.1% | 4/12/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $21.00 -> $35.00 | Low | View details for SVB Securities rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 4/12/2023 |
CORT Corcept Therapeutics | $38.39
+0.7% | 4/11/2023 | Initiated by | SVB Securities | - | Market Perform | $25.00 | Low | View details for SVB Securities rating of Corcept Therapeutics (NASDAQ:CORT) on 4/11/2023 |
IPHA Innate Pharma | $2.17
-4.0% | 4/10/2023 | Target Raised by | SVB Securities | - | | $9.00 -> $10.00 | Low | View details for SVB Securities rating of Innate Pharma (NASDAQ:IPHA) on 4/10/2023 |
ACLX Arcellx | $77.08
+0.2% | 3/30/2023 | Target Raised by | SVB Securities | - | | $35.00 -> $39.00 | Low | View details for SVB Securities rating of Arcellx (NASDAQ:ACLX) on 3/30/2023 |
REGN Regeneron Pharmaceuticals | $1,154.88
+0.1% | 3/27/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $834.00 -> $976.00 | Low | View details for SVB Securities rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 3/27/2023 |
INCY Incyte | $66.25
+4.2% | 3/24/2023 | Upgraded by | SVB Securities | - | Underperform -> Market Perform | $61.00 | Low | View details for SVB Securities rating of Incyte (NASDAQ:INCY) on 3/24/2023 |
PTCT PTC Therapeutics | $33.76
-0.7% | 3/17/2023 | Initiated by | SVB Securities | - | Market Perform | $48.00 | Low | View details for SVB Securities rating of PTC Therapeutics (NASDAQ:PTCT) on 3/17/2023 |
CNTA Centessa Pharmaceuticals | $16.39
-3.5% | 3/17/2023 | Initiated by | SVB Securities | - | Outperform | $6.00 | Low | View details for SVB Securities rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 3/17/2023 |
HALO Halozyme Therapeutics | $63.04
+1.2% | 3/16/2023 | Downgraded by | SVB Securities | - | Outperform -> Market Perform | $42.00 | Low | View details for SVB Securities rating of Halozyme Therapeutics (NASDAQ:HALO) on 3/16/2023 |
FULC Fulcrum Therapeutics | $3.14
-1.3% | 3/10/2023 | Target Lowered by | SVB Securities | - | | $18.00 -> $10.00 | Low | View details for SVB Securities rating of Fulcrum Therapeutics (NASDAQ:FULC) on 3/10/2023 |
MORF Morphic | $56.99
| 3/8/2023 | Target Raised by | SVB Securities | - | | $45.00 -> $56.00 | Low | View details for SVB Securities rating of Morphic (NASDAQ:MORF) on 3/8/2023 |
ARGX argenx | $538.62
+0.1% | 3/3/2023 | Target Raised by | SVB Securities | - | | $430.00 -> $435.00 | Low | View details for SVB Securities rating of argenx (NASDAQ:ARGX) on 3/3/2023 |
AHCO AdaptHealth | $11.42
+4.8% | 3/1/2023 | Target Lowered by | SVB Securities | - | | $30.00 -> $23.00 | Low | View details for SVB Securities rating of AdaptHealth (NASDAQ:AHCO) on 3/1/2023 |
MDRX Veradigm | $9.90
+1.0% | 3/1/2023 | Target Lowered by | SVB Securities | - | | $24.00 -> $17.00 | Low | View details for SVB Securities rating of Veradigm (NASDAQ:MDRX) on 3/1/2023 |
GPCR Structure Therapeutics | $40.18
-1.6% | 2/28/2023 | Initiated by | SVB Securities | - | Outperform | $33.00 | Low | View details for SVB Securities rating of Structure Therapeutics (NASDAQ:GPCR) on 2/28/2023 |
IRON Disc Medicine | $48.78
+2.1% | 2/28/2023 | Initiated by | SVB Securities | - | Outperform | $36.00 | Low | View details for SVB Securities rating of Disc Medicine (NASDAQ:IRON) on 2/28/2023 |
NKTR Nektar Therapeutics | $1.26
-4.2% | 2/24/2023 | Target Lowered by | SVB Securities | - | | $5.00 -> $3.00 | N/A | View details for SVB Securities rating of Nektar Therapeutics (NASDAQ:NKTR) on 2/24/2023 |
BPMC Blueprint Medicines | $86.07
-3.2% | 2/24/2023 | Target Lowered by | SVB Securities | - | | $45.00 -> $38.00 | Low | View details for SVB Securities rating of Blueprint Medicines (NASDAQ:BPMC) on 2/24/2023 |
MRNA Moderna | $69.53
+1.8% | 2/24/2023 | Downgraded by | SVB Securities | - | Market Perform -> Underperform | $111.00 -> $93.00 | Low | View details for SVB Securities rating of Moderna (NASDAQ:MRNA) on 2/24/2023 |
IONS Ionis Pharmaceuticals | $40.52
-4.0% | 2/23/2023 | Target Lowered by | SVB Securities | - | | $34.00 -> $27.00 | Low | View details for SVB Securities rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/23/2023 |
TDOC Teladoc Health | $8.24
+1.9% | 2/23/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $34.00 | Low | View details for SVB Securities rating of Teladoc Health (NYSE:TDOC) on 2/23/2023 |
ABBV AbbVie | $195.09
+0.5% | 2/10/2023 | Upgraded by | SVB Securities | - | Underperform -> Market Perform | $135.00 -> $153.00 | Low | View details for SVB Securities rating of AbbVie (NYSE:ABBV) on 2/10/2023 |
VRTX Vertex Pharmaceuticals | $488.21
+0.6% | 2/8/2023 | Target Lowered by | SVB Securities | - | | $374.00 -> $365.00 | Low | View details for SVB Securities rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 2/8/2023 |
CI The Cigna Group | $366.45
+0.5% | 2/8/2023 | Target Lowered by | SVB Securities | - | | $335.00 -> $309.00 | Low | View details for SVB Securities rating of The Cigna Group (NYSE:CI) on 2/8/2023 |
META Meta Platforms | $529.79
+1.0% | 2/2/2023 | Target Raised by | SVB Securities | - | Outperform | $220.00 -> $255.00 | Low | View details for SVB Securities rating of Meta Platforms (NASDAQ:META) on 2/2/2023 |
AMGN Amgen | $334.86
+0.7% | 2/2/2023 | Target Lowered by | SVB Securities | - | | $282.00 -> $267.00 | Low | View details for SVB Securities rating of Amgen (NASDAQ:AMGN) on 2/2/2023 |
DNLI Denali Therapeutics | $30.50
-0.9% | 1/30/2023 | Initiated by | SVB Securities | - | Outperform | $50.00 | Low | View details for SVB Securities rating of Denali Therapeutics (NASDAQ:DNLI) on 1/30/2023 |
BHVN Biohaven | $38.88
+2.1% | 1/24/2023 | Initiated by | SVB Securities | - | Outperform | $24.00 | Low | View details for SVB Securities rating of Biohaven (NYSE:BHVN) on 1/24/2023 |
